Ar­genx de­buts first DTC for myas­the­nia gravis med Vyv­gart even as MG com­mu­ni­ty ef­fort con­tin­ues

In a quick turn to DTC, ar­genx is rolling out its first cam­paign for myas­the­nia gravis med Vyv­gart just a month af­ter FDA ap­proval.

Four re­al MG pa­tients star in the in­au­gur­al TV ad that, while un­brand­ed and not men­tion­ing Vyv­gart by name, does fo­cus on a “new FDA-ap­proved treat­ment” for the de­bil­i­tat­ing au­toim­mune dis­ease.

A voiceover in the 30-sec­ond com­mer­cial asks the ques­tion why do pa­tients want a new treat­ment? Each pa­tient is then fea­tured in suc­ces­sion as they an­swer with rea­sons like “be­cause we want to go out to din­ner with friends” or “be­cause in fam­i­ly pho­tos, we want to be able to smile.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER